Resources/
Phil Blog
Phil Blog
Leveraging Territory Performance Monitoring to Scale Hub Performance
From ever-increasing payer utilization management requirements and declining gross-to-net margins, life sciences companies face complex commercialization challenges. Specialty and specialty-lite retail brands are increasingly leaning on hub services as a key component of their go-to-market strategy to elevate patient access and brand outcomes as conventional commercialization strategies continue to wain in their overall effectiveness. However, most manufacturers struggle to drive high adoption of and engagement with their patient services programs
Why Quality Scripts are Crucial to Ensuring Pharmacy Coverage for Your Brand
When prescribing a specialty or specialty-lite therapy with hub services, a healthcare provider can often jumpstart getting their patient started on the treatment by sending the script directly to the hub. However, six out of ten providers report that they are uncertain of the insurance benefits information needed to start patients on complex therapies, and submitting the wrong information can hold up a prescription from the get-go. Health insurance plans typically have specific requirements that must be met before covering an expensive branded therapy
Meet Makena Zannini, Head of Business Optimization at Phil
We’re delighted to introduce Makena Zannini, Head of Business Optimization at Phil. Discover Makena’s fascinating background and her analytical superpowers that help us move mountains. Tell me a little bit about yourself I grew up in a small town in Pennsylvania and ended up making my way to New York City
Hubs, Digital Pharmacies, and Specialty Pharmacies: What Pharma Access Teams Should Know
The evolution of healthcare consumer expectations and proliferation of expensive specialty and specialty-lite therapies have led to the rise of innovative solutions to clear an often onerous path to prescribed treatment. In 2022, specialty drugs accounted for 55% of the net spending in the pharmaceutical market, up from 28% in 2011. And an estimated 3 out of 4 patients who try to fill a new prescription for a recently launched brand are unsuccessful due to payer controls
How Biopharma Companies Can Support Patients with High Deductible Health Plans
In 2023, a growing number of patients are enrolled in high deductible health plans (HDHPs), which require members to pay healthcare costs out-of-pocket until they meet their annual deductible amount before the plan starts covering eligible costs. A recent analysis found that over half of American private-sector workers are now enrolled in HDHPs – a 14.5% increase from 2017. The current minimum deductible for an HDHP set by the IRS is $1,500 for an individual and $3,000 for a family
Ready to learn more?
Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.
